Matthias B. Jaffé

Pervasis Therapeutics, Inc. is a clinical stage company developing a broad portfolio of biologically active therapeutics. The company was founded by Robert S. Langer Jr. and Helen Marie Nugent in 2004 and is headquartered in Waltham, MA.

Alantos Pharmaceuticals Holding, Inc. manufactures bio-pharmaceutical products. The firm develops small molecule compounds for inflammatory cytokine pathways. The company was founded in 1999 and is headquartered in Thousand Oaks, CA.

Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA.

YourBio Health, Inc. develops health monitoring products. It is developing an array of products based on the company's proprietary TAP? (Touch Activated Phlebotomy) painless blood collection platform. The company was founded by Richard Rox Anderson, Joerg Lahann, Robert S. Langer Jr., Douglas A. Levinson and Samir Mitragotri in 2008 and is headquartered in Medford, MA.

Alantos Pharmaceuticals AG develops and manufactures molecule pharmaceuticals for arthritic and metabolic diseases. The company was founded in 1999 and is headquartered in Heidelberg, Germany.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA.

LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA.